Abstract

Scott &White Memorial Hospital provides comprehensive, high quality health care for a 38 county area in Central Texas. Since the early 1900s, Scott &White has demonstrated leadership in providing innovative cancer care emphasized by medical education and research. Continuing with this tradition of quality care for the community, Scott &White seeks to continue its funding for the Community Clinical Oncology Program (CCOP) to support these objectives. The mission of the Scott &White Cancer Institute is """"""""to provide the most comprehensive, highest quality cancer care, focusing on the prevention and treatment of cancer, enhanced by the application of scientific discoveries to ultimately improve the care of those living with cancer at Scott &White and throughout the world."""""""" Funding from the NCI since 1997 for our CCOP has enabled the Cancer Institute to evolve into a recognized leader in clinical cancer research and treatment for our service area. The proposed CCOP consists of the Scott &White component and Southwest Regional Cancer Center affiliate. The component and affiliate will work together in promoting innovative cooperative group studies in the community and contributing to quality research through refinement of processes to identify patients for protocol enrollment. The objectives for the CCOP will be to further support the commitment to delivering research options to the community that include cancer control, prevention, and treatment studies. The CCOP will continue to build on the existing strategies to recruit minority participants onto NCI-sponsored protocols by establishing relationships and by providing access to services in underserved areas. The disease-specific teams were developed to expedite patient discussion and treatment plan decisions, will continue to improve processes with a patient-centered approach to treatment. Community-based involvement will be strengthened by increasing participation in cancer-related organizations that support the goal of eradicating life-threatening cancers through education, research, and providing access for underserved areas. A consistent growth in the Central Texas area, increased health plan participation and the expansion of outreach clinics has placed an increasing demand for cancer services at Scott and White.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA074647-15
Application #
8080998
Study Section
Special Emphasis Panel (ZCA1-SRRB-Y (J1))
Program Officer
O'Mara, Ann M
Project Start
1997-08-01
Project End
2013-05-31
Budget Start
2011-06-01
Budget End
2012-05-31
Support Year
15
Fiscal Year
2011
Total Cost
$461,207
Indirect Cost

  Institution

Name
Scott and White Memorial Hospital
Department
Type
DUNS #
076697960
City
Temple
State
TX
Country
United States
Zip Code
76504

  Publications

Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Erba, Harry P; Othus, Megan; Walter, Roland B et al. (2014) Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432. Leuk Res 38:329-33
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5

Showing the most recent 10 out of 97 publications